Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein

Tanya Golubchik*1, Katrina A. Lythgoe*1, Matthew Hall1, Luca Ferretti1, Helen R. Fryer1, George MacIntyre-Cockett^{1,2}, Mariateresa de Cesare^{1,2}, Amy Trebes², Paolo Piazza², David Buck², John A. Todd², The COVID-19 Genomics UK (COG-UK) consortium³, Christophe Fraser¹. David Bonsall^{1,2}

*Equal contribution

Corresponding authors: David.Bonsall@bdi.ox.ac.uk, Tanya.Golubchik@bdi.ox.ac.uk

¹Big Data Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7FL, UK.

²Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford, Old Road Campus, Oxford OX3 7BN, UK. ³www.cogconsortium.uk. Full list of names and affiliations are in the Appendix.

Abstract

A new variant of SARS-CoV-2 has emerged which is increasing in frequency, primarily in the South East of England (lineage B.1.1.7 (1); VUI-202012/01). One potential hypothesis is that infection with the new variant results in higher viral loads, which in turn may make the virus more transmissible. We found higher (sequence derived) viral loads in samples from individuals infected with the new variant with median inferred viral loads were three-fold higher in individuals with the new variant. Most of the new variants were sampled in Kent and Greater London. We observed higher viral loads in Kent compared to Greater London for both the new variant and other circulating lineages. Outside Greater London, the variant has higher viral loads, whereas within Greater London, the new variant does not have significantly higher viral loads compared to other circulating lineages. Higher variant viral loads outside Greater London could be due to demographic effects, such as a faster variant growth rate compared to other lineages or concentration in particular age-groups. However, our analysis does not exclude a causal link between infection with the new variant and higher viral loads. This is a preliminary analysis and further work is needed to investigate any potential causal link between infection with this new variant and higher viral loads, and whether this results in higher transmissibility, severity of infection, or affects relative rates of symptomatic and asymptomatic infection

Document Description and Purpose:

This is an updated report submitted to NERVTAG in December 2020 as part of urgent investigations into the new variant of SARS-COV-2 (VUI-202012/01). It makes full use of (and is restricted to) all sequence data and associated metadata available to us at the time this original report was submitted and remains provisional. Under normal circumstances more genomes and metadata would be obtained and included before making this report public. We will update this preprint when more genomes and metadata are available and before submitting for peer review.

Background

On 14 December 2020 a new variant of SARS-CoV-2 circulating in the UK was reported (2, 3), characterised by the N501Y mutation in the receptor binding domain (RBD) of Spike, the ΔH69/V70 deletion, and numerous other mutations (1). The rise in frequency of this variant is associated with a sharp increase in reported cases in the South East of England, raising concerns that the variant could be more transmissible. We performed a rapid analysis to investigate whether the new variant is associated with higher viral loads, since higher viral loads may indicate increased transmissibility.

Methods

As members of the COG-UK consortium (https://www.cogconsortium.uk/), we sequenced RT-QPCR SARS-CoV-2 positive samples originating from four UK Lighthouse laboratories, which provide Pillar 2 COVID-19 testing services. The samples were sequenced using veSEQ, our quantitative sequencing approach for which the number of unique mapped reads is correlated with, and thus can be used as a proxy for, viral load. For a full description of the sequencing protocol see (4, 5).

We used log_{10} (mapped reads) as a proxy for viral load (see fig S1 in (5)). Comparisons between distributions of log₁₀ (mapped reads) were made using Welsh t-test (two-tailed), with p-values combined using Stouffer's method where appropriate. We also performed a multivariate logistic regression analysis.

Number of unique mapped reads is negatively correlated with Ct value

Given the known negative correlation between viral load and cycle threshold (Ct) values (6) obtained during PCR testing (7), we first confirmed a strong negative correlation between log₁₀ (unique mapped reads) and Ct values for samples that we sequenced from Lighthouse laboratories (linear regression, r^2 =0.43, p<<0.001, Fig. 1).




Figure 1. A strong negative correlation between Ct value and log₁₀(number of mapped reads). Number of uniquely mapped reads per sample can be used as a proxy for viral load. The Ct value shown is the maximum Ct value obtained from Majora (the COG database) from retrospective data for all Lighthouse laboratories that supply Ct data; log₁₀ of uniquely mapped (deduplicated) reads obtained with veSEQ platform correlates well with Ct. This does not include samples in this report since Ct values were not yet available.

The new variant is associated with higher viral loads

The N501Y mutation is strongly linked with other mutations characterising the new variant (VUI-202012/01) in our dataset, including the ΔH69/V70 deletion, and therefore we used Y501 as a marker of the new variant. The ΔH69/V70 deletion alone is not a specific marker of VUI-202012/01 in our data, while lineage B.1.1.70, which is currently present in Wales and in some cases carries Y501 but never the deletion, was not present in our data.

We identified 88 samples that produced consensus sequences with the Y501 variant. All variant samples were taken between 31 Oct 2020 and 13 Nov 2020, and therefore we only considered samples (Y501 and N501) taken during this period, since Ct values have been shown to vary by calendar time (7).

When comparing the number of unique mapped reads in the Y501 variant samples (median $\log_{10}(\text{reads})=4.64$, N=88) with that in the to N501 samples (median $\log_{10}(\text{reads})=4.16$, N=1299), we found higher counts in the former (Welch t-Test p=0.014; Fig. 1). This is equivalent to around 3-fold higher median viral loads in the Y501 variant samples compared to N501 samples.




Figure 1: Higher numbers of mapped reads in samples with the Y501 variant. Box and scatter plots of unique mapped reads, stratified according to variant. Points within each batch are jittered to aid visualisation. Horizontal lines in boxplots represent the median and the interquartile range. The Y501 variant has a higher number of mapped reads, whereas the ΔH69/V70 deletion only has a higher number of mapped reads in the presence of the N501Y mutation.

This result remained significant when we controlled for batch (Fig. 3a, p=0.011, combined p-value via Stouffer's method), but not Lighthouse laboratory (Fig. 3b, p=0.052). The correlation between the new variant and viral load is also associated with a relative paucity of samples with lower ($<10^3$) mapped reads among Y501 samples (Fig. 1, p=0.0053, chi-squared test; 10³ logged mapped reads is equivalent to a viral load of ~10⁴ copies per reaction, max Ct~28). When comparing samples with just the ΔH69/V70 deletion (without the Y501 variant) to samples without the deletion, we did not find a significant difference in log_{10} (reads) (p=0.86; controlling for batch p=0.56, and for Lighthouse lab p=0.54) (Fig. 1).




Figure 3. Higher numbers of mapped reads in samples exhibiting the Y501 variant Box and scatter plots of unique mapped reads, stratified by (a) batch date and (b) anonymised Lighthouse lab. There is no significant difference among batches or Lighthouse labs for N501 samples (p>0.1 for all pairwise comparisons). Points within each batch are jittered to aid visualisation. Horizontal lines in boxplots represent the median and the interquartile range.

Viral loads differ by sampling location

To test whether the difference in viral loads for samples with the new variant could in part be explained by geographic effects, we considered the sampling location (adm2 district) where this information was available. Of the 88 Y501 variants sampled, 24 were in Greater London, 46 in Kent, and in lower numbers (N=1-5) in other areas (Bristol, Essex, Hampshire, Leicestershire, Norfolk, Surrey and West Sussex). Regardless of variant presence, all samples from Greater London had significantly lower viral loads than those from other locations (p=0.0016, Welch's t-test), and the association between Y501 and higher viral load was not significant in this region (p=0.91; Fig. 4). Outside Greater London, viral loads for Y501 were significantly higher than for N501 (p=0.0068). Within Kent, the location with the greatest number of Y501 samples, Y501 viral loads were not significantly higher than N501 viral loads (p=0.089). These results indicate a correlation between infection with the new variant (VUI-202012/01) and (inferred) viral load outside Greater London, although we are currently underpowered to draw firm conclusions. The lack of association within Greater London could be due to lack of power, or to demographic or epidemiological differences in London compared with the other locations.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.




Figure 4. Number of mapped reads varies by sampling location

Box and scatter plots of unique mapped reads, stratified by sampling location. Points within each batch are jittered to aid visualisation. Horizontal lines in boxplots represent the median and the interguartile range. Only sampling locations with at least one Y501 sample were included.

In a multivariate logistic regression analysis for variables associated with higher viral load (Table 1), the Y501 variant was associated with a fivefold increase in odds of $>=10^3$ mapped reads (p=0.036). The fitted model with interaction terms suggest a much smaller effect of the variant outside Kent, with the total odds increase reduced to 1.75 for Greater London and 1.24 for other regions, but the interaction term coefficients were not statistically significant (p=0.27 and p=0.16, respectively). Thus, if the association of the variant with a paucity of low viral load samples is stronger in Kent compared to other areas (e.g. due to epidemiological, demographic, or sampling differences), we lack the necessary power to demonstrate it. No other variables showed evidence of an association.

Table 1. Logistic regression analysis, identifying variables associated with >=10³ mapped reads.

	Odds ratio (95% CI)
Y105	5.078* (1.111, 23.218)
Region (reference: Kent)	
Greater London	0.675 (0.371, 1.227)
Other	$0.869 \ (0.476, 1.588)$
Lighthouse lab (reference: 1)	30000000000000000000000000000000000000
2	1.148 (0.703, 1.874)
3	1.183 (0.610, 2.296)
4	0.906 (0.512, 1.605)
Batch date (reference: 30 Nov)	
7 Dec	$0.822 \ (0.575, 1.173)$
14 Dec	0.955 (0.502, 1.816)
Interaction: $Y105 \times Greater London$	$0.345 \ (0.053, 2.248)$
Interaction: $Y105 \times Other region$	$0.245 \ (0.034, 1.771)$
Observations	1,376
Note:	*p<0.05; **p<0.01; ***p<

Odds ratios for each variable and 95% confidence intervals for those ratios are presented. Lighthouse labs are anonymised as in Fig. 2.

Caveats and Limitations

This is a preliminary analysis, and other factors could explain the (inferred) higher viral loads in samples with the new variant (VUI-202012/01), in addition to a working hypothesis that there is a causal effect of the new variant on within-host virus abundance. Whether the correlation is causative (infections with the new variant have higher viral loads) or correlative (e.g. due to epidemiological dynamics, demographics of individuals infected with the new variant, and/or sampling) warrants further study.

Individuals contributing samples in this analysis were tested as part of the test and trace program, which is primarily aimed towards individuals seeking a test following the onset of symptoms. We observed a broad spectrum of viral loads among the samples we sequenced. Given known associations between lower viral loads and later infection (8), and higher viral loads at the onset of symptoms, this suggests our full dataset consists of individuals in both early and late stages of symptomatic infection. Whilst we do not a priori expect there to be a systematic difference in the timing of sampling relative to infection, in an exponentially growing population the expectation is to sample relatively more people early in infection (9). Whether or not early sampling-bias supports an effect on inferred viral loads will depend on the relative epidemiological dynamics of the new and other variants. If, for example, VUI-202012/01 is growing faster, this could result in a bias for it to be sampled earlier. This is consistent with the relative paucity of VUI-202012/01 samples with low viral load.

In addition, VUI-202012/01 might be circulating within particular demographics (e.g. age groups) that tend to have higher viral loads when sampled. This may explain the apparently different patterns in Greater London and elsewhere. Focussed transmission within a particular demographic group is also more likely during the early stages of epidemic growth of a given lineage, before it disperses into the wider population. We were unable to test these hypotheses as we did not have demographic data relating to the sampled individuals with the new variant. We also cannot rule out other additional confounding effects and recommend that such effects are investigated further.

Future prospects

A number of processess could have caused the rapid growth of the new variant (VUI-202012/01), including founder effects, or biological mechanisms that increase its transmissibility. Higher viral loads are one such potential mechanism: Transmissibility of viruses is understood to be higher in individuals who exhibit higher viral loads (10) and in HIV viral load is partly determined by virus genotype (11). Our observation of higher inferred viral loads in individuals infected with the new variant suggests that increased transmissibility of the new variant is plausible, but important caveats remain.

We recommend further investigations to evaluate this hypothesis. We note that we have used Y501 as a marker for the new variant; a large number of other mutations also characterise this new variant lineage (1), and therefore Y501 per se might not be causing the effect (if there is one). We also note that higher viral loads can be associated with higher levels of viral virulence, and therefore links between the new variant and the severity of infection should be monitored carefully (12).

Whether or not observed higher viral loads associated with this variant are a direct cause of infection with the variant, a consequence of faster epidemic growth, or linked to particular demographics, our data are consistent with rapid growth of this specific lineage.

References

- A. Rambaut et al., Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations (2020), (available at https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563).
- S. A. Kemp, R. P. Datir, D. A. Collier, I. Ferreira, A. Carabelli, W. Harvey, D. L. Robertson, R. K. Gupta, Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/V70. Cold Spring Harbor Laboratory (2020), p. 2020.12.14.422555.
- Update on new SARS-CoV-2 variant and how COG-UK tracks emerging mutations -COG-UK Consortium, (available at https://www.cogconsortium.uk/news item/update-on-new-sars-cov-2-variant-and-how-c og-uk-tracks-emerging-mutations/).
- D. Bonsall, T. Golubchik, M. de Cesare, M. Limbada, B. Kosloff, G. MacIntyre-Cockett, M. Hall, C. Wymant, M. Azim Ansari, L. Abeler-Dörner, A. Schaap, A. Brown, E. Barnes, E. Piwowar-Manning, S. Eshleman, E. Wilson, L. Emel, R. Hayes, S. Fidler, H. Ayles, R. Bowden, C. Fraser, HPTN 071 (PopART) Team, A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings. J. Clin. Microbiol. **58** (2020), doi:10.1128/JCM.00382-20.
- K. A. Lythgoe, M. Hall, L. Ferretti, M. de Cesare, G. MacIntyre-Cockett, A. Trebes, M. Andersson, N. Otecko, E. L. Wise, N. Moore, J. Lynch, S. Kidd, N. Cortes, M. Mori, R. Williams, G. Vernet, A. Justice, A. Green, S. M. Nicholls, M. Azim Ansari, L. Abeler-Dörner, C. E. Moore, T. E. A. Peto, D. W. Evre, R. Shaw, P. Simmonds, D. Buck, J. A. Todd, on behalf of OVSG Analysis Group, T. R. Connor, A. da Silva Filipe, J. Shepherd, E. C. Thomson, The COVID-19 Genomics UK (COG-UK) consortium, D. Bonsall, C. Fraser, T. Golubchik, Within-host genomics of SARS-CoV-2. Cold Spring

- Harbor Laboratory (2020), p. 2020.05.28.118992.
- Public Health England, Cycle threshold (Ct) in SARS-CoV-2 RT-PCR (2020), (available at https://www.gov.uk/government/publications/cycle-threshold-ct-in-sars-cov-2-rt-pcr).
- 7. A. Sarah Walker, E. Pritchard, T. House, J. V. Robotham, P. J. Birrell, I. Bell, J. I. Bell, J. N. Newton, J. Farrar, I. Diamond, R. Studley, J. Hay, K.-D. Vihta, T. Peto, N. Stoesser, P. C. Matthews, D. W. Eyre, K. B. Pouwels, the COVID-19 Infection Survey team, Viral load in community SARS-CoV-2 cases varies widely and temporally. medRxiv, 2020.10.25.20219048 (2020).
- 8. S. M. Kissler, J. R. Fauver, C. Mack, S. W. Olesen, C. Tai, K. Y. Shiue, C. C. Kalinich, S. Jednak, I. M. Ott, C. B. F. Vogels, J. Wohlgemuth, J. Weisberger, J. DiFiori, D. J. Anderson, J. Mancell, D. D. Ho, N. D. Grubaugh, Y. H. Grad, SARS-CoV-2 viral dynamics in acute infections. *medRxiv*, 2020.10.21.20217042 (2020).
- 9. J. A. Hay, L. Kennedy-Shaffer, S. Kanjilal, M. Lipsitch, M. J. Mina, Estimating epidemiologic dynamics from single cross-sectional viral load distributions. medRxiv, 2020.10.08.20204222 (2020).
- 10. X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan, X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, L. Zhao, F. Zhang, B. J. Cowling, F. Li, G. M. Leung, Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672-675 (2020).
- 11. C. Fraser, K. Lythgoe, G. E. Leventhal, G. Shirreff, T. Déirdre Hollingsworth, S. Alizon, S. Bonhoeffer, Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary Perspective. Science. 343 (2014), doi:10.1126/science.1243727.
- 12. Public Health England, PHE investigating a novel strain of COVID-19. GOV.UK (2020), (available at https://www.gov.uk/government/news/phe-investigating-a-novel-strain-of-covid-19).

Acknowledgments

We are grateful to Lorne Lornie, Angie Green, The Oxford Genomics Centre and The Wellcome Centre for Human Genetics, for all their support in generating the data for this study.

Ethics

The COVID-19 Genomics UK (COG-UK) consortium study protocol was approved by the Public Health England Research Ethics and Governance Group (reference: R&D NR0195) on the 8th of April 2020. The decision was communicated to Professor Sharon Peacock by Dr Elizabeth Coates, Head of Research Governance, PHE Research Support and Governance Office.

Funding

The UK COVID-19 Genomics Consortium (COG UK) is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department

of Health. KAL and HRF are supported by The Wellcome Trust and The Royal Society (107652/Z/15/Z) and by Li Ka Shing Foundation funding awarded to KL. TG, MH, LF, MdC, GMC, CF and DB are supported by Li Ka Shing Foundation funding awarded to CF.

Appendix: COG-UK Full list of consortium names and affiliations

Funding acquisition, leadership, supervision, metadata curation, project administration, samples, logistics, Sequencing, analysis, and Software and analysis tools:

Thomas R Connor ^{33, 34}, and Nicholas J Loman ¹⁵.

Leadership, supervision, sequencing, analysis, funding acquisition, metadata curation, project administration, samples, logistics, and visualisation:

Samuel C Robson 68.

Leadership, supervision, project administration, visualisation, samples, logistics, metadata curation and software and analysis tools:

Tanya Golubchik ²⁷.

Leadership, supervision, metadata curation, project administration, samples, logistics sequencing and analysis:

M. Estee Torok 8, 10.

Project administration, metadata curation, samples, logistics, sequencing, analysis, and software and analysis tools:

William L Hamilton 8, 10.

Leadership, supervision, samples logistics, project administration, funding acquisition sequencing and analysis:

David Bonsall ²⁷.

Leadership and supervision, sequencing, analysis, funding acquisition, visualisation and software and analysis tools:

Ali R Awan 74.

Leadership and supervision, funding acquisition, sequencing, analysis, metadata curation, samples and logistics:

Sally Corden³³.

Leadership supervision, sequencing analysis, samples, logistics, and metadata curation: Ian Goodfellow 11.

Leadership, supervision, sequencing, analysis, samples, logistics, and Project administration:

Darren L Smith 60, 61.

Project administration, metadata curation, samples, logistics, sequencing and analysis: Martin D Curran 14, and Surendra Parmar 14.

Samples, logistics, metadata curation, project administration sequencing and analysis: James G Shepherd ²¹.

Sequencing, analysis, project administration, metadata curation and software and analysis

Matthew D Parker ³⁸ and Dinesh Aggarwal ^{1, 2, 3}.

Leadership, supervision, funding acquisition, samples, logistics, and metadata curation: Catherine Moore ³³

Leadership, supervision, metadata curation, samples, logistics, sequencing and analysis: Derek J Fairley^{6, 88}, Matthew W Loose ⁵⁴, and Joanne Watkins ³³.

Metadata curation, sequencing, analysis, leadership, supervision and software and analysis tools:

Matthew Bull 33, and Sam Nicholls 15.

Leadership, supervision, visualisation, sequencing, analysis and software and analysis tools:

David M Aanensen 1, 30.

Sequencing, analysis, samples, logistics, metadata curation, and visualisation: Sharon Glaysher 70

Metadata curation, sequencing, analysis, visualisation, software and analysis tools: Matthew Bashton ⁶⁰, and Nicole Pacchiarini ³³.

Sequencing, analysis, visualisation, metadata curation, and software and analysis tools: Anthony P Underwood 1, 30.

Funding acquisition, leadership, supervision and project administration:

Thushan I de Silva 38, and Dennis Wang 38.

Project administration, samples, logistics, leadership and supervision:

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license.

Monique Andersson²⁸, Anoop J Chauhan ⁷⁰, Mariateresa de Cesare ²⁶, Catherine Ludden ^{1,3}, and Tabitha W Mahungu ⁹¹.

Sequencing, analysis, project administration and metadata curation:

Rebecca Dewar 20, and Martin P McHugh 20.

Samples, logistics, metadata curation and project administration:

Natasha G Jesudason ²¹, Kathy K Li MBBCh ²¹, Rajiv N Shah ²¹, and Yusri Taha ⁶⁶.

Leadership, supervision, funding acquisition and metadata curation:

Kate E Templeton 20.

Leadership, supervision, funding acquisition, sequencing and analysis:

Simon Cottrell ³³, Justin O'Grady ⁵¹, Andrew Rambaut ¹⁹, and Colin P Smith ⁹³.

Leadership, supervision, metadata curation, sequencing and analysis:

Matthew T.G. Holden 87, and Emma C Thomson 21.

Leadership, supervision, samples, logistics and metadata curation:

Samuel Moses 81,82.

Sequencing, analysis, leadership, supervision, samples and logistics:

Meera Chand ⁷, Chrystala Constantinidou ⁷¹, Alistair C Darby ⁴⁶, Julian A Hiscox ⁴⁶, Steve Paterson ⁴⁶, and Meera Unnikrishnan ⁷¹.

Sequencing, analysis, leadership and supervision and software and analysis tools:

Andrew J Page 51, and Erik M Volz 96.

Samples, logistics, sequencing, analysis and metadata curation:

Charlotte J Houldcroft ⁸, Aminu S Jahun ¹¹, James P McKenna ⁸⁸, Luke W Meredith ¹¹, Andrew Nelson ⁶¹, Sarojini Pandey ⁷², and Gregory R Young ⁶⁰.

Sequencing, analysis, metadata curation, and software and analysis tools:

Anna Price ³⁴, Sara Rey ³³, Sunando Roy ⁴¹, Ben Temperton ⁴⁹, and Matthew Wyles ³⁸.

Sequencing, analysis, metadata curation and visualisation:

Stefan Rooke¹⁹, and Sharif Shaaban ⁸⁷.

Visualisation, sequencing, analysis and software and analysis tools:

Helen Adams ³⁵, Yann Bourgeois ⁶⁹, Katie F Loveson ⁶⁸, Áine O'Toole ¹⁹, and Richard Stark ⁷¹.

Project administration, leadership and supervision:

Ewan M Harrison ^{1, 3}, David Heyburn ³³, and Sharon J Peacock ^{2, 3}

Project administration and funding acquisition:

David Buck ²⁶, and Michaela John³⁶

Sequencing, analysis and project administration:

Dorota Jamrozy 1, and Joshua Quick 15

Samples, logistics, and project administration:

Rahul Batra 78, Katherine L Bellis 1,3, Beth Blane 3, Sophia T Girgis 3, Angie Green 26, Anita Justice 28, Mark Kristiansen 41, and Rachel J Williams 41.

Project administration, software and analysis tools:

Radoslaw Poplawski¹⁵.

Project administration and visualisation:

Garry P Scarlett 69.

Leadership, supervision, and funding acquisition:

John A Todd ²⁶, Christophe Fraser ²⁷, Judith Breuer ^{40,41}, Sergi Castellano ⁴¹, Stephen L Michell ⁴⁹, Dimitris Gramatopoulos ⁷³, and Jonathan Edgeworth ⁷⁸.

Leadership, supervision and metadata curation:

Gemma L Kay 51.

Leadership, supervision, sequencing and analysis:

Ana da Silva Filipe ²¹, Aaron R Jeffries ⁴⁹, Sascha Ott ⁷¹, Oliver Pybus ²⁴, David L Robertson ²¹, David A Simpson ⁶, and Chris Williams ³³.

Samples, logistics, leadership and supervision:

Cressida Auckland 50, John Boyes 83, Samir Dervisevic 52, Sian Ellard 49,50, Sonia Goncalves1, Emma J Meader ⁵¹, Peter Muir ², Husam Osman ⁹⁵, Reenesh Prakash ⁵², Venkat Sivaprakasam ¹⁸, and Ian B Vipond ².

Leadership, supervision and visualisation

Jane AH Masoli 49,50.

Sequencing, analysis and metadata curation

Nabil-Fareed Alikhan ⁵¹, Matthew Carlile ⁵⁴, Noel Craine ³³, Sam T Haldenby ⁴⁶, Nadine Holmes ⁵⁴, Ronan A Lyons ³⁷, Christopher Moore ⁵⁴, Malorie Perry ³³, Ben Warne ⁸⁰, and Thomas Williams 19.

Samples, logistics and metadata curation:

Lisa Berry ⁷², Andrew Bosworth ⁹⁵, Julianne Rose Brown ⁴⁰, Sharon Campbell ⁶⁷, Anna Casey ¹⁷, Gemma Clark ⁵⁶, Jennifer Collins ⁶⁶, Alison Cox ^{43, 44}, Thomas Davis ⁸⁴, Gary Eltringham ⁶⁶, Cariad Evans ^{38, 39}, Clive Graham ⁶⁴, Fenella Halstead ¹⁸, Kathryn Ann Harris ⁴⁰, Christopher Holmes 58, Stephanie Hutchings 2, Miren Iturriza-Gomara 46, Kate Johnson 38, 39, Katie Jones ⁷², Alexander J Keeley ³⁸, Bridget A Knight ^{49, 50}, Cherian Koshy⁹⁰, Steven Liggett ⁶³, Hannah Lowe 81, Anita O Lucaci 46, Jessica Lynch 25, 29, Patrick C McClure 55, Nathan Moore 31, Matilde Mori ^{25, 29, 32}, David G Partridge ^{38, 39}, Pinglawathee Madona ^{43, 44}, Hannah M Pymont ², Paul Anthony Randell ^{43,44}, Mohammad Raza ^{38,39}, Felicity Ryan ⁸¹, Robert Shaw ²⁸, Tim J Sloan ⁵⁷, and Emma Swindells ⁶⁵.

Sequencing, analysis, Samples and logistics:

Alexander Adams ³³, Hibo Asad ³³, Alec Birchley ³³, Tony Thomas Brooks ⁴¹, Giselda Bucca ⁹³, Ethan Butcher 70, Sarah L Caddy 13, Laura G Caller 2, 3, 12, Yasmin Chaudhry 11, Jason Coombes ³³, Michelle Cronin ³³, Patricia L Dyal ⁴¹, Johnathan M Evans ³³, Laia Fina ³³, Bree Gatica-Wilcox ³³, Iliana Georgana ¹¹, Lauren Gilbert ³³, Lee Graham ³³, Danielle C Groves ³⁸, Grant Hall ¹¹, Ember Hilvers ³³, Myra Hosmillo ¹¹, Hannah Jones ³³, Sophie Jones ³³, Fahad A Khokhar ¹³, Sara Kumziene-Summerhayes ³³, George MacIntyre-Cockett ²⁶, Rocio T Martinez Nunez 94, Caoimhe McKerr 33, Claire McMurray 15, Richard Myers 7, Yasmin Nicole Panchbhaya 41, Malte L Pinckert 11, Amy Plimmer 33, Joanne Stockton 15, Sarah Taylor 33, Alicia Thornton ⁷, Amy Trebes ²⁶, Alexander J Trotter ⁵¹, Helena Jane Tutill ⁴¹, Charlotte A Williams ⁴¹, Anna Yakovleva ¹¹ and Wen C Yew ⁶².

Sequencing, analysis and software and analysis tools:

Mohammad T Alam ⁷¹, Laura Baxter ⁷¹, Olivia Boyd ⁹⁶, Fabricia F. Nascimento ⁹⁶, Timothy M Freeman ³⁸, Lily Geidelberg ⁹⁶, Joseph Hughes ²¹, David Jorgensen ⁹⁶, Benjamin B Lindsey ³⁸, Richard J Orton ²¹, Manon Ragonnet-Cronin ⁹⁶ Joel Southgate ^{33, 34,} and Sreenu Vattipally ²¹.

Samples, logistics and software and analysis tools:

Igor Starinskij ²³.

Visualisation and software and analysis tools:

Joshua B Singer ²¹, Khalil Abudahab ^{1,30}, Leonardo de Oliveira Martins ⁵¹, Thanh Le-Viet ⁵¹ ,Mirko Menegazzo ³⁰ ,Ben EW Taylor ^{1, 30}, and Corin A Yeats ³⁰.

Project Administration:

Sophie Palmer³, Carol M Churcher³, Alisha Davies³³, Elen De Lacy³³, Fatima Downing³³, Sue Edwards ³³, Nikki Smith ³⁸, Francesc Coll ⁹⁷, Nazreen F Hadjirin ³ and Frances Bolt ^{44, 45}.

Leadership and supervision:

Alex Alderton¹, Matt Berriman¹, Ian G Charles ⁵¹, Nicholas Cortes ³¹, Tanya Curran ⁸⁸, John Danesh¹, Sahar Eldirdiri ⁸⁴, Ngozi Elumogo ⁵², Andrew Hattersley ^{49, 50}, Alison Holmes ^{44, 45}, Robin Howe ³³, Rachel Jones ³³, Anita Kenyon ⁸⁴, Robert A Kingsley ⁵¹, Dominic Kwiatkowski ¹, ⁹, Cordelia Langford¹, Jenifer Mason⁴⁸, Alison E Mather ⁵¹, Lizzie Meadows ⁵¹, Sian Morgan ³⁶, James Price 44, 45, Trevor I Robinson 48, Giri Shankar 33, John Wain 51, and Mark A Webber 51.

Metadata curation:

Declan T Bradley 5, 6, Michael R Chapman 1, 3, 4, Derrick Crooke 28, David Eyre 28, Martyn Guest ³⁴, Huw Gulliver ³⁴, Sarah Hoosdally ²⁸, Christine Kitchen ³⁴, Ian Merrick ³⁴, Siddharth Mookerjee 44, 45, Robert Munn 34, Timothy Peto 28, Will Potter 52, Dheeraj K Sethi 52, Wendy Smith ⁵⁶, Luke B Snell ^{75, 94}, Rachael Stanley ⁵², Claire Stuart ⁵² and Elizabeth Wastenge²⁰.

Sequencing and analysis:

Erwan Acheson ⁶, Safiah Afifi ³⁶, Elias Allara ^{2,3}, Roberto Amato ¹, Adrienn Angyal ³⁸, Elihu Aranday-Cortes ²¹, Cristina Ariani ¹, Jordan Ashworth ¹⁹, Stephen Attwood ²⁴, Alp Aydin ⁵¹, David J Baker ⁵¹, Carlos E Balcazar ¹⁹, Angela Beckett ⁶⁸ Robert Beer ³⁶, Gilberto Betancor ⁷⁶, Emma Betteridge ¹, David Bibby ⁷, Daniel Bradshaw ⁷, Catherine Bresner ³⁴, Hannah E Bridgewater 71, Alice Broos 21, Rebecca Brown 38, Paul E Brown 71, Kirstyn Brunker 22, Stephen N Carmichael 21, Jeffrey K. J. Cheng 71, Dr Rachel Colquhoun 19, Gavin Dabrera 7, Johnny Debebe 54, Eleanor Drury 1, Louis du Plessis 24, Richard Eccles 46, Nicholas Ellaby 7, Audrey Farbos 49, Ben Farr 1, Jacqueline Findlay 41, Chloe L Fisher 74, Leysa Marie Forrest 41, Sarah Francois 24, Lucy R. Frost 71, William Fuller 34, Eileen Gallagher 7, Michael D Gallagher 19, Matthew Gemmell ⁴⁶, Rachel AJ Gilroy ⁵¹, Scott Goodwin ¹, Luke R Green ³⁸, Richard Gregory ⁴⁶, Natalie Groves ⁷, James W Harrison ⁴⁹, Hassan Hartman ⁷, Andrew R Hesketh ⁹³, Verity Hill ¹⁹, Jonathan Hubb ⁷, Margaret Hughes ⁴⁶, David K Jackson ¹, Ben Jackson ¹⁹, Keith James ¹ ,Natasha Johnson ²¹, Ian Johnston ¹, Jon-Paul Keatley ¹, Moritz Kraemer ²⁴, Angie Lackenby ⁷, Mara Lawniczak ¹, David Lee ⁷, Rich Livett ¹, Stephanie Lo ¹, Daniel Mair ²¹, Joshua Maksimovic ³⁶, Nikos Manesis ⁷, Robin Manley ⁴⁹, Carmen Manso ⁷, Angela Marchbank ³⁴, Inigo Martincorena ¹, Tamyo Mbisa ⁷, Kathryn McCluggage ³⁶, JT McCrone ¹⁹, Shahjahan Miah ⁷, Michelle L Michelsen ⁴⁹, Mari Morgan ³³, Gaia Nebbia ⁷⁸, Charlotte Nelson ⁴⁶, Jenna Nichols ²¹ ,Paola Niola ⁴¹ , Kyriaki Nomikou ²¹ ,Steve Palmer ¹ , Naomi Park ¹ , Yasmin A Parr ¹ , Paul J Parsons ³⁸, Vineet Patel ⁷, Minal Patel ¹, Clare Pearson ^{2, 1}, Steven Platt ⁷, Christoph Puethe ¹, Mike Quail ¹, Jayna Raghwani ²⁴, Lucille Rainbow ⁴⁶, Shavanthi Rajatileka ¹, Mary Ramsay ⁷, Paola C Resende Silva ^{41, 42}, Steven Rudder 51, Chris Ruis ³, Christine M Sambles ⁴⁹, Fei Sang 54, Ulf Schaefer7, Emily Scher 19, Carol Scott 1, Lesley Shirley 1, Adrian W Signell 76, John Sillitoe ¹, Christen Smith ¹, Dr Katherine L Smollett ²¹, Karla Spellman ³⁶, Thomas D Stanton ¹⁹, David J Studholme ⁴⁹, Grace Taylor-Joyce ⁷¹, Ana P Tedim ⁵¹, Thomas Thompson ⁶,

Nicholas M Thomson 51, Scott Thurston1, Lily Tong 21, Gerry Tonkin-Hill 1, Rachel M Tucker 38, Edith E Vamos ⁴, Tetyana Vasylyeva²⁴, Joanna Warwick-Dugdale ⁴⁹, Danni Weldon ¹, Mark Whitehead ⁴⁶, David Williams ⁷, Kathleen A Williamson ¹⁹, Harry D Wilson ⁷⁶, Trudy Workman ³⁴, Muhammad Yasir⁵¹, Xiaoyu Yu¹⁹, and Alex Zarebski ²⁴.

Samples and logistics:

Evelien M Adriaenssens 51, Shazaad S Y Ahmad 2, 47, Adela Alcolea-Medina 59, 77, John Allan 60, Patawee Asamaphan ²¹, Laura Atkinson ⁴⁰, Paul Baker ⁶³, Jonathan Ball ⁵⁵, Edward Barton ⁶⁴, Mathew A Beale¹, Charlotte Beaver¹, Andrew Beggs ¹⁶, Andrew Bell ⁵¹, Duncan J Berger ¹, Louise Berry. ⁵⁶, Claire M Bewshea ⁴⁹, Kelly Bicknell ⁷⁰, Paul Bird ⁵⁸, Chloe Bishop ⁷, Tim Boswell ⁵⁶, Cassie Breen ⁴⁸, Sarah K Buddenborg¹, Shirelle Burton-Fanning ⁶⁶, Vicki Chalker ⁷, Joseph G Chappell 55, Themoula Charalampous 78,94, Claire Cormie3, Nick Cortes29,25, Lindsay J Coupland ⁵², Angela Cowell ⁴⁸, Rose K Davidson ⁵³, Joana Dias ³, Maria Diaz ⁵¹, Thomas Dibling¹, Matthew J Dorman¹, Nichola Duckworth⁵⁷, Scott Elliott⁷⁰, Sarah Essex⁶³, Karlie Fallon 58, Theresa Feltwell 8, Vicki M Fleming 56, Sally Forrest 3, Luke Foulser 1, Maria V Garcia-Casado¹, Artemis Gavriil ⁴¹, Ryan P George ⁴⁷, Laura Gifford ³³, Harmeet K Gill ³, Jane Greenaway 65, Luke Griffith53, Ana Victoria Gutierrez51, Antony D Hale 85, Tanzina Haque 91, Katherine L Harper 85, Ian Harrison 7, Judith Heaney 89, Thomas Helmer 58, Ellen E Higginson 3, Richard Hopes ², Hannah C Howson-Wells ⁵⁶, Adam D Hunter ¹, Robert Impey ⁷⁰, Dianne Irish-Tavares 91, David A Jackson 1, Kathryn A Jackson 46, Amelia Joseph 56, Leanne Kane 1, Sally Kay ¹, Leanne M Kermack ³, Manjinder Khakh ⁵⁶, Stephen P Kidd ^{29, 25, 31}, Anastasia Kolyva ⁵¹, Jack CD Lee ⁴⁰, Laura Letchford ¹, Nick Levene ⁷⁹, Lisa J Levett ⁸⁹, Michelle M Lister ⁵⁶, Allyson Lloyd ⁷⁰, Joshua Loh ⁶⁰, Louissa R Macfarlane-Smith ⁸⁵, Nicholas W Machin ^{2,47}, Mailis Maes³, Samantha McGuigan¹, Liz McMinn¹, Lamia Mestek-Boukhibar⁴¹, Zoltan Molnar⁶, Lynn Monaghan ⁷⁹, Catrin Moore ²⁷, Plamena Naydenova ³, Alexandra S Neaverson ¹, Rachel Nelson ¹, Marc O Niebel ²¹, Elaine O'Toole⁴⁸, Debra Padgett ⁶⁴, Gaurang Patel ¹, Brendan Al Payne ⁶⁶, Liam Prestwood ¹, Veena Raviprakash ⁶⁷, Nicola Reynolds ⁸⁶, Alex Richter ¹⁶, Esther Robinson 95, Hazel A Rogers1, Aileen Rowan 96, Garren Scott 64, Divya Shah 40, Nicola Sheriff 67, Graciela Sluga, Emily Souster¹, Michael Spencer-Chapman¹, Sushmita Sridhar ^{1, 3}, Tracey Swingler ⁵³, Julian Tang⁵⁸, Graham P Taylor⁹⁶, Theocharis Tsoleridis ⁵⁵, Lance Turtle⁴⁶, Sarah Walsh ⁵⁷, Michelle Wantoch ⁸⁶, Joanne Watts ⁴⁸, Sheila Waugh ⁶⁶, Sam Weeks ⁴¹, Rebecca Williams³¹, Iona Willingham⁵⁶, Emma L Wise ^{25, 29, 31}, Victoria Wright ⁵⁴, Sarah Wyllie ⁷⁰, and Jamie Young 3.

Software and analysis tools

Amy Gaskin³³, Will Rowe ¹⁵, and Igor Siveroni ⁹⁶.

Visualisation:

Robert Johnson 96.

1 Wellcome Sanger Institute, 2 Public Health England, 3 University of Cambridge, 4 Health Data Research UK, Cambridge, 5 Public Health Agency, Northern Ireland ,6 Queen's University Belfast 7 Public Health England Colindale, 8 Department of Medicine, University of Cambridge, 9 University of Oxford, 10 Departments of Infectious Diseases and Microbiology, Cambridge University Hospitals NHS Foundation Trust; Cambridge, UK, 11 Division of Virology, Department of Pathology, University of Cambridge, 12 The Francis Crick Institute, 13 Cambridge Institute for Therapeutic Immunology and Infectious Disease, Department of Medicine, 14 Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge, UK, 15 Institute of Microbiology and Infection, University of Birmingham, 16 University of Birmingham, 17 Queen Elizabeth Hospital, 18 Heartlands Hospital, 19 University of Edinburgh, 20 NHS Lothian, 21 MRC-University of Glasgow Centre for Virus Research, 22 Institute of Biodiversity, Animal Health & Comparative Medicine, University of Glasgow, 23 West of Scotland Specialist Virology Centre, 24 Dept Zoology, University of Oxford, 25 University of Surrey, 26 Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, 27 Big Data Institute, Nuffield Department of Medicine, University of Oxford, 28 Oxford University Hospitals NHS Foundation Trust, 29 Basingstoke Hospital, 30 Centre for Genomic Pathogen Surveillance, University of Oxford, 31 Hampshire Hospitals NHS Foundation Trust, 32 University of Southampton, 33 Public Health Wales NHS Trust, 34 Cardiff University, 35 Betsi Cadwaladr University Health Board, 36 Cardiff and Vale University Health Board, 37 Swansea University, 38 University of Sheffield, 39 Sheffield Teaching Hospitals, 40 Great Ormond Street NHS Foundation Trust, 41 University College London, 42 Oswaldo Cruz Institute, Rio de Janeiro 43 North West London Pathology, 44 Imperial College Healthcare NHS Trust, 45 NIHR Health Protection Research Unit in HCAI and AMR, Imperial College London, 46 University of Liverpool, 47 Manchester University NHS Foundation Trust, 48 Liverpool Clinical Laboratories, 49 University of Exeter, 50 Royal Devon and Exeter NHS Foundation Trust, 51 Quadram Institute Bioscience, University of East Anglia, 52 Norfolk and Norwich University Hospital, 53 University of East Anglia, 54 Deep Seq, School of Life Sciences, Queens Medical Centre, University of Nottingham, 55 Virology, School of Life Sciences, Queens Medical Centre, University of Nottingham, 56 Clinical Microbiology Department, Queens Medical Centre, 57 PathLinks, Northern Lincolnshire & Goole NHS Foundation Trust, 58 Clinical Microbiology, University Hospitals of Leicester NHS Trust, 59 Viapath, 60 Hub for Biotechnology in the Built Environment, Northumbria University, 61 NU-OMICS Northumbria University, 62 Northumbria University, 63 South Tees Hospitals NHS Foundation Trust, 64 North Cumbria Integrated Care NHS Foundation Trust, 65 North Tees and Hartlepool NHS Foundation Trust, 66 Newcastle Hospitals NHS Foundation Trust, 67 County Durham and Darlington NHS Foundation Trust, 68 Centre for Enzyme Innovation, University of Portsmouth, 69 School of Biological Sciences, University of Portsmouth, 70 Portsmouth Hospitals NHS Trust, 71 University of Warwick, 72 University Hospitals Coventry and Warwickshire, 73 Warwick Medical School and Institute of Precision Diagnostics, Pathology, UHCW NHS Trust, 74 Genomics Innovation Unit, Guy's and St. Thomas' NHS Foundation Trust, 75 Centre for Clinical Infection & Diagnostics Research, St. Thomas' Hospital and Kings College London, 76 Department of Infectious Diseases, King's College London, 77 Guy's and St. Thomas' Hospitals NHS Foundation Trust, 78 Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, 79 Princess Alexandra Hospital Microbiology Dept., 80 Cambridge University Hospitals NHS Foundation Trust, 81 East Kent Hospitals University NHS Foundation Trust, 82 University of Kent, 83 Gloucestershire Hospitals NHS Foundation Trust, 84 Department of Microbiology, Kettering General Hospital, 85 National Infection Service, PHE and Leeds Teaching Hospitals Trust, 86 Cambridge Stem Cell Institute, University of Cambridge, 87 Public Health Scotland, 88 Belfast Health & Social Care Trust, 89 Health Services Laboratories, 90 Barking, Havering and Redbridge University Hospitals NHS Trust, 91 Royal Free NHS Trust, 92 Maidstone and Tunbridge Wells NHS Trust, 93 University of Brighton, 94 Kings College London, 95 PHE Heartlands, 96 Imperial College London, 97 Department of Infection Biology, London School of Hygiene and Tropical Medicine.